Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Rheumatic Disease
Interventions
DRUG

Methotrexate

Continue throughout perioperative period

DRUG

Sulfasalazine

Continue throughout perioperative period

DRUG

Hydroxychloroquine

Continue throughout perioperative period

DRUG

Leflunomide

Continue throughout perioperative period

DRUG

Azathioprine

Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

DRUG

Mycophenolate

Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

DRUG

Cyclosporine

Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

DRUG

Tacrolimus

Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

DRUG

Etanercept

Control group: Schedule surgery 2 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose

DRUG

Adalimumab

Control group: Schedule surgery 3 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose

DRUG

Golimumab

"Control group: Schedule surgery 5 weeks after last administered 4-week subcutaneous dose or 9 weeks after last administered 8-week intravenous dose.~Intervention group: Schedule surgery 2 weeks after last administered 4-week subcutaneous dose or 4 weeks after last administered 8-week intravenous dose."

DRUG

Certolizumab

Control group: Schedule surgery 5 weeks after last administered dose. Intervention group: Schedule surgery 2 weeks after last administered dose.

DRUG

Infliximab

"Control group: Schedule surgery 9 weeks after last administered intravenous dose.~Intervention group: Schedule surgery 4 weeks after last administered dose."

BIOLOGICAL

Rituximab

Control: Schedule 7 months after last administered dose. Intervention group: Schedule 3 months after last administered dose.

BIOLOGICAL

Belimumab

"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."

BIOLOGICAL

Tocilizumab

"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."

BIOLOGICAL

Anakinra

Control group: Schedule surgery 2 days after last administered daily dose. Experimental group: Schedule surgery 1 day after last administered daily dose.

BIOLOGICAL

Canakinumab

Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.

BIOLOGICAL

Abatacept

"Control group: Schedule surgery 2 weeks after last administered weekly subcutaneous dose or 5 weeks after last administered monthly intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly subcutaneous dose or 2 weeks after last administered monthly intravenous dose."

BIOLOGICAL

Secukinumab

"Control group: Schedule surgery 5 weeks after last administered subcutaneous dose.~Intervention group: Schedule surgery 2 weeks after last administered subcutaneous dose."

BIOLOGICAL

Ixekizumab

Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.

BIOLOGICAL

Bimekizumab

Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4 weeks after last administered 8-week dose

BIOLOGICAL

Ustekinumab

Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6 weeks after last administered 12-week dose.

BIOLOGICAL

Guselkumab

Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4.5 weeks after last administered 8-week dose.

BIOLOGICAL

Risankizumab

Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6-7 weeks after last administered 12-week dose.

DRUG

Tofacitinib

Control group: Schedule surgery 4 days after last administered daily dose. Intervention group: Schedule surgery 2 days after last administered daily dose.

DRUG

Upadacitinib

Control group: Withhold 4 days prior to surgery Intervention group: Withhold 2 days prior to surgery

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER